Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=84 Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Metastatic Melanoma · Recurrent Melanoma · Stage III Cutaneous Melanoma AJCC v7
Primary: Progression-free Survival — 6.9; 2.3 months — p=0.002
Phase 2 N=65 Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Clofarabine — 15 mg/m^2 x 4 days (6-9)
Phase 2 N=289 Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
Nonalcoholic Steatohepatitis
Primary: Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular…
Phase 2 N=58 A Trial of Sertraline in Young Children With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Change in Mullen Scales of Early Learning - Expressive Language Raw Score — 19.69; 18.19; 21.81; 20.31 score on a scale
Phase 2 N=29 Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Primary: Change in Average Morning Fasting Free Testosterone Blood Concentrations From Baseline — 0.91; 1.03 nmol/L — p=0.353
Phase 2 N=24 Effectiveness of Pulmozyme in Infants With Cystic Fibrosis
Cystic Fibrosis
Primary: Chest CT (High Resolution Computed Tomography (HRCT) Score) — 3.7; 6.1 Score points
Phase 2 N=120 A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
Diabetes Mellitus Type 2
Primary: Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 — 0.0005; 0.0029; 0.0007; 0.0004 Percent Change
Phase 2 N=41 Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
Adult Idiopathic Generalized Osteoporosis
Primary: Change in Lumbar Spine Bone Mineral Density (LS-BMD) on Active Medication — 10.1; 4.1 percentage of change
Phase 2 N=26 Colchicine and CRP in Atrial Fibrillation and AF Ablation
Atrial Fibrillation
Primary: Change in C-reactive Protein — 6.4; 2.7; 2.9; 5.9 ng/mL — p=0.038
Phase 2 N=45 Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer
Primary: (Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity…
Phase 2 N=280 P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Contrast to Noise Ratio (CNR) Difference — -10.59; 2.18; 8.66; 14.45 Ratio — p=0.1858
Phase 2 N=10 Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Alpha 1 Antitrypsin Deficiency
Primary: Changes in Inflammatory Biomarkers in Bronchoalveolar Lavage Fluid — 14.3; 8.1; 10.3; 379.9 pg/ml — p=<0.05
Phase 2 N=24 Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
Type 2 Diabetes Mellitus
Primary: Change in Area Above Basal (AAB) for Glucose — 66458; 72566 mg/dL x min — p=0.43
Phase 2 N=21 Targeted Fusion Biopsy of the Prostate
Prostatic Neoplasms
Primary: Percentage of Cores Positive for Cancer — 32.0; 4.5 percentage of positive core samples